MIP-3α-gp100-TRP2 DNA vaccine

The MIP-3α-gp100-TRP2 DNA vaccine is an experimental, preclinical-stage therapeutic cancer DNA vaccine developed by researchers at the Johns Hopkins Bloomberg School of Public Health. The vaccine construct consists of a pCMVe mammalian expression plasmid encoding the chemokine MIP-3α (also known as CCL20) genetically fused to two melanoma-associated antigens: gp100 (amino acids 25–235 of the human melanoma antigen) and Tyrosinase-Related Protein 2 (TRP2). Its mechanism of action involves targeting the CCR6 receptor on immature dendritic cells via the MIP-3α component, which directs the fused tumor antigens to these professional antigen-presenting cells to enhance the adaptive immune response against melanoma. In preclinical studies using the B16F10 mouse model, the vaccine is typically administered via intramuscular electroporation and has shown enhanced efficacy when combined with CpG adjuvants, type-I interferon, and epigenetic modulators like 5-Aza-2'-deoxycytidine to overcome immunosuppressive mechanisms in the tumor microenvironment.

Other names

MIP3α-gp100-TRP2 vaccineMIP-3α-antigen DNA vaccineMIP3α-antigen vaccineCCL20-gp100-TRP2 DNA vaccineCCL-20-gp100-TRP2 DNA vaccineCCL 20-gp100-TRP2 DNA vaccine